Phaseline

Targets › FANCA

FANCA (Fanconi anemia group A protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology.

DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. (UniProt, O15360)

Open in Phaseline: the race on FANCA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rocket PharmaceuticalsRP-L102
Lentiviral vector-mediated ex vivo gene transfer of FANCA gene into CD34+ hematopoietic st
FANCAPhase 2Fanconi Anemia Complementation Group A–

Conditions

Fanconi Anemia Complementation Group A (1)

Modalities

protein or peptide (1)

Companies

Rocket Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.